Table 1 Demographic and clinical characteristics of patients with advanced-stage NSCLC with available spirometry.
Non-COPD | COPD | p value | |
|---|---|---|---|
Patients | 96 | 138 | |
Age | 0.52 | ||
< 65 years | 55 (57.2) | 62 (45.0) | |
≥ 65 years | 41 (42.7) | 76 (55.0) | |
Female | 41 (32.7) | 44 (31.9) | 0.42 |
Smoking habits | < 0.01 | ||
Never-smoker | 7 (7.3) | 1 (0.7) | |
Ex-smoker | 70 (72.9) | 96 (69.6) | |
Current smoker | 18 (18.8) | 40 (29.0) | |
Pack-years, median (IQR) | 35 (20–50) | 40 (30–50) | < 0.01 |
Performance status, median (IQR) | 1 (1–2) | 1 (1–2) | 0.78 |
Survival | |||
PFS, median days (IQR) | 167 (86–564) | 263 (109–667) | 0.01 |
OS, median days (IQR) | 413 (164–779) | 494 (228–904) | 0.01 |
Histological type | 0.37 | ||
Adenocarcinoma | 67 (69.8) | 87 (63.0) | |
Squamous cell carcinoma | 21 (21.9) | 38 (27.5.0) | |
Other NSCLC | 7 (7.3) | 13 (8.7) | |
PDL-1 status | 0.42 | ||
< 1% | 33 (34.4) | 33 (23.9) | |
1–49% | 24 (25.0) | 36 (26.1) | |
≥ 50% | 16 (16.7) | 30 (21.7) | |
Undetermined | 34 (35.4) | 39 (28.2) | |
ICI druga | 0.43 | ||
Nivolumab | 49 (51.0) | 78 (56.5) | |
Pembrolizumab | 31 (32.3) | 42 (30.4) | |
Atezolizumab | 12 (12.5) | 16 (11.6) | |
Durvalumab | 3 (3.1) | 1 (0.7) | |
Number of lines of treatmenta | 0.04 | ||
1 | 25 (26.0) | 20 (14.5) | |
2 | 53 (55.2) | 91 (65.9) | |
3 | 16 (16.7) | 23 (16.7) | |
4 | 1 (1.0) | 3 (2.2) | |
≥ 5 | 0 (0.0) | 0 (0.0) | |
Treatment modality | < 0.01 | ||
ICI monotherapy | 74 (77.1) | 120 (86.9) | |
With chemotherapy | 22 (22.9) | 18 (13.0) | |
Number of ICI cure, median (IQR) | 10 (6–26) | 12 (6–27) | < 0.01 |
